학술논문

The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway.
Document Type
Article
Source
Frontiers in Oncology; 2023, p1-14, 14p
Subject
ERLOTINIB
NON-small-cell lung carcinoma
EPIDERMAL growth factor receptors
PHOSPHATIDYLINOSITOL 3-kinases
CANCER cells
CANCER relapse
Language
ISSN
2234943X
Abstract
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)